0000000000403486

AUTHOR

Raffaele A. Calogero

showing 3 related works from this author

Look for methods, not conclusions

2019

Qualunque sia l'esito effettivo di un'indagine su un caso di presunta manipolazione dei dati, ci sono alcuni principi fermi che sono sempre veri e alcuni errori che devono essere evitati.

Cancer ResearchMolecular biologyPeer ReviewScienceImmunologyScientific MisconductSettore AGR/13 - Chimica Agrariamethods; verification experimental datasetresearch integrityDiseasesmethodsCellular and Molecular NeuroscienceCorrespondenceScientific methodHumansexperimental datasetlcsh:QH573-671Scientific misconductPeer Review Researchlcsh:CytologyResearchCell BiologyEngineering ethicsverificationPsychologyHumans; Peer Review Research; Science; Scientific Misconduct
researchProduct

TRPA1 channel is a cardiac target of mIGF-1/SIRT1 signaling.

2014

Cardiac overexpression of locally acting muscle-restricted (m)IGF-1 and the consequent downstream activation of NAD+-dependent protein deacetylase sirtuin 1 (SIRT1) trigger potent cardiac antioxidative and antihypertrophic effects. Transient receptor potential (TRP) cation channel A1 (TRPA1) belongs to the TRP ion channel family of molecular detectors of thermal and chemical stimuli that activate sensory neurons to produce pain. Recently, it has been shown that TRPA1 activity influences blood pressure, but the significance of TRPA1 in the cardiovascular system remains elusive. In the present work, using genomic screening in mouse hearts, we found that TRPA1 is a target of mIGF-1/SIRT1 sign…

Member 1PhysiologyTransgeneHeart; Insulin-like growth factor-1; Member 1; Sirtuin 1; Subfamily A; Transient receptor potential cation channelBlood PressurePharmacologymedicine.disease_causeTransient receptor potential channelMiceTransient Receptor Potential ChannelsSirtuin 1Physiology (medical)medicineAnimalsMyocytes CardiacInsulin-Like Growth Factor IPromoter Regions GeneticTRPA1 Cation ChannelbiologySirtuin 1AntagonistIGF-1 SIRT1 TRPA1 micefood and beveragesHeartTransient receptor potential cation channelInsulin-like growth factor-1Subfamily APurinesbiology.proteinProtein deacetylaseAcetanilidesNAD+ kinaseSignal transductionCardiology and Cardiovascular Medicinepsychological phenomena and processesOxidative stressSignal Transduction
researchProduct

BRAF mutations in non-small cell lung cancer : has finally Janus opened the door?

2016

Abstract: B-Raf mutations occur in about 1-2% of non-small cell lung cancers (NSCLC). These mutations generate a permanent activation of the mitogen activated protein kinase (MAPK) pathway, which promotes tumor growth and proliferation. In the present review, we discuss B-Raf mutation epidemiology, diagnostic methods to detect B-Raf mutations, the role of B-Raf as a driver mutation and a potential therapeutic target in NSCLC. The results of clinical trials involving B-Raf or MAPK pathway inhibitors for the treatment of NSCLC are also discussed. Clinical trials evaluating B-Raf inhibitors in BRAF mutated NSCLC patients have shown promising results, and larger prospective studies are warrante…

MAPK/ERK pathwayProto-Oncogene Proteins B-rafmedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentCellProtein Kinase Inhibitormedicine.disease_causeBioinformaticsNSCLCTargeted therapy03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungmedicineHumans030212 general & internal medicineB-Raf inhibitorLung cancerProtein Kinase InhibitorsB-Raf inhibitorsMutationHematologybiologybusiness.industryB-RafB-Raf; B-Raf inhibitors; Drug; Mutation; NSCLC; Oncology; Hematology; Geriatrics and GerontologyHematologymedicine.diseaseLung NeoplasmClinical trialmedicine.anatomical_structureOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisMitogen-activated protein kinaseMutationbiology.proteinCancer researchHuman medicineDrugGeriatrics and GerontologybusinessHumanCritical reviews in oncology, hematology
researchProduct